113 related articles for article (PubMed ID: 32782544)
1. Patients with advanced non-small cell lung cancer with EGFR mutations in addition to complex mutations treated with osimertinib have a poor clinical outcome: A real-world data analysis.
Chang N; Duan J; Wang L; Dong Z; Liu Z
Oncol Lett; 2020 Sep; 20(3):2266-2272. PubMed ID: 32782544
[TBL] [Abstract][Full Text] [Related]
2. Real-World Data Of Osimertinib In Patients With Pretreated Non-Small Cell Lung Cancer: A Retrospective Study.
Mu Y; Xing P; Hao X; Wang Y; Li J
Cancer Manag Res; 2019; 11():9243-9251. PubMed ID: 31802944
[TBL] [Abstract][Full Text] [Related]
3. Resistance Profile of Osimertinib in Pre-treated Patients With EGFR T790M-Mutated Non-small Cell Lung Cancer.
Fernandes MGO; Sousa C; Jacob M; Almeida L; Santos V; Araújo D; Novais Bastos H; Magalhães A; Cirnes L; Moura CS; Queiroga H; Cruz-Martins N; Hespanhol V
Front Oncol; 2021; 11():602924. PubMed ID: 34026599
[No Abstract] [Full Text] [Related]
4. Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation.
Yoshimura A; Yamada T; Okura N; Takeda T; Hirose K; Kubota Y; Shiotsu S; Hiranuma O; Chihara Y; Tamiya N; Kaneko Y; Uchino J; Takayama K
Cancers (Basel); 2019 Mar; 11(3):. PubMed ID: 30875919
[TBL] [Abstract][Full Text] [Related]
5. The Status of the EGFR T790M Mutation is associated with the Clinical Benefits of Osimertinib Treatment in Non-small Cell Lung Cancer Patients: A Meta-Analysis.
Zhao Z; Li L; Wang Z; Duan J; Bai H; Wang J
J Cancer; 2020; 11(11):3106-3113. PubMed ID: 32231715
[No Abstract] [Full Text] [Related]
6. Impact of
Igawa S; Ono T; Kasajima M; Ishihara M; Hiyoshi Y; Kusuhara S; Nishinarita N; Fukui T; Kubota M; Sasaki J; Hisashi M; Yokoba M; Katagiri M; Naoki K
Cancer Manag Res; 2019; 11():4883-4892. PubMed ID: 31213907
[No Abstract] [Full Text] [Related]
7. Mechanisms of resistance to osimertinib.
Lazzari C; Gregorc V; Karachaliou N; Rosell R; Santarpia M
J Thorac Dis; 2020 May; 12(5):2851-2858. PubMed ID: 32642198
[TBL] [Abstract][Full Text] [Related]
8. Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in lung squamous cell cancer: A case report.
Zhang Y; Chen HM; Liu YM; Peng F; Yu M; Wang WY; Xu H; Wang YS; Lu Y
World J Clin Cases; 2019 May; 7(10):1221-1229. PubMed ID: 31183356
[TBL] [Abstract][Full Text] [Related]
9. Osimertinib for Previously Treated Patients With Advanced EGFR T790M Mutation-Positive NSCLC: Tolerability and Diagnostic Methods From an Expanded Access Program.
Santos ES; Kaplan B; Kirshner E; Croft EF; Sequist LV; Chau M; Munley J; Oxnard GR
Oncol Ther; 2018 Jun; 6(1):45-58. PubMed ID: 32700141
[TBL] [Abstract][Full Text] [Related]
10. A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group.
Jiang T; Su C; Ren S; Cappuzzo F; Rocco G; Palmer JD; van Zandwijk N; Blackhall F; Le X; Pennell NA; Zhou C;
J Thorac Dis; 2018 Jul; 10(7):3909-3921. PubMed ID: 30174832
[TBL] [Abstract][Full Text] [Related]
11. Osimertinib as first-line therapy in advanced NSCLC: a profile of its use.
Scott LJ
Drugs Ther Perspect; 2018; 34(8):351-357. PubMed ID: 30631243
[TBL] [Abstract][Full Text] [Related]
12. A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With
Morimoto K; Sawada R; Yamada T; Azuma K; Ito K; Goto Y; Kimura H; Harada T; Shiotsu S; Tamiya N; Chihara Y; Takeda T; Hiranuma O; Hasegawa I; Morimoto Y; Iwasaku M; Tokuda S; Takayama K
JTO Clin Res Rep; 2022 Sep; 3(9):100388. PubMed ID: 36082280
[TBL] [Abstract][Full Text] [Related]
13. T790M mutant copy number quantified via ddPCR predicts outcome after osimertinib treatment in lung cancer.
Li JY; Ho JC; Wong KH
Oncotarget; 2018 Jun; 9(46):27929-27939. PubMed ID: 29963252
[TBL] [Abstract][Full Text] [Related]
14. Upregulation of long non‑coding RNA LINC00460 in EGFR‑mutant lung cancer indicates a poor prognosis in patients treated with osimertinib.
Nakano Y; Isobe K; Yoshizawa T; Urabe N; Homma S; Kishi K
Oncol Lett; 2023 Sep; 26(3):380. PubMed ID: 37559586
[TBL] [Abstract][Full Text] [Related]
15. Small Cell Lung Cancer Transformation as a Resistance Mechanism to Osimertinib in Epidermal Growth Factor Receptor-Mutated Lung Adenocarcinoma: Case Report and Literature Review.
Leonetti A; Minari R; Mazzaschi G; Gnetti L; La Monica S; Alfieri R; Campanini N; Verzè M; Olivani A; Ventura L; Tiseo M
Front Oncol; 2021; 11():642190. PubMed ID: 33981604
[No Abstract] [Full Text] [Related]
16. Case Report: A Metabolic Complete Response to Upfront Osimertinib in a Smoker Non-Small Cell Lung Cancer Patient Harbouring
Simionato F; Calvetti L; Cosci M; Scarparo S; Aprile G
Onco Targets Ther; 2020; 13():12027-12031. PubMed ID: 33262603
[TBL] [Abstract][Full Text] [Related]
17. Exposure-Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung Cancer.
Rodier T; Puszkiel A; Cardoso E; Balakirouchenane D; Narjoz C; Arrondeau J; Fallet V; Khoudour N; Guidi M; Vidal M; Declèves X; Csajka C; Alexandre J; Cadranel J; Fabre E; Wislez M; Goldwasser F; Blanchet B
Pharmaceutics; 2022 Sep; 14(9):. PubMed ID: 36145591
[TBL] [Abstract][Full Text] [Related]
18. The potential therapeutic regimen for overcoming resistance to osimertinib due to rare mutations in NSCLC.
Han R; Lin C; Zhang C; Kang J; Lu C; Zhang Y; Wang Y; Hu C; He Y
iScience; 2023 Jul; 26(7):107105. PubMed ID: 37416479
[TBL] [Abstract][Full Text] [Related]
19. Corrigendum to "Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)" [Lung Cancer 186 (2023) 107426].
Sakata Y; Saito G; Sakata S; Oya Y; Tamiya M; Suzuki H; Shibaki R; Okada A; Yokoyama T; Matsumoto H; Otsuki T; Sato Y; Junji U; Tsukita Y; Inaba M; Ikeda H; Arai D; Maruyama H; Hara S; Tsumura S; Morinaga J; Sakagami T
Lung Cancer; 2024 Feb; 188():107450. PubMed ID: 38160082
[No Abstract] [Full Text] [Related]
20. Osimertinib in untreated epidermal growth factor receptor (
Gregorc V; Lazzari C; Karachaliou N; Rosell R; Santarpia M
Transl Lung Cancer Res; 2018 Apr; 7(Suppl 2):S165-S170. PubMed ID: 29782558
[No Abstract] [Full Text] [Related]
[Next] [New Search]
